List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 376 studies with search of: Open Studies | "Melanoma"
Include studies that are not seeking new volunteers.
Hide studies with unknown recruitment status.
  Display Options
Rank Status Study
1 Recruiting Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Conditions: Malignant Skin Melanoma T0;   Stage III Melanoma;   Stage IV Melanoma;   Amplification
Intervention: Drug: Nilotinib
2 Recruiting Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: axitinib;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: 3'-deoxy-3'-[18F]fluorothymidine;   Procedure: positron emission tomography
3 Recruiting Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma
Conditions: Hereditary Multiple Melanoma;   Melanoma (Skin)
Interventions: Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: molecular genetic technique;   Genetic: mutation analysis;   Other: laboratory biomarker analysis;   Procedure: mutation carrier screening;   Procedure: study of high risk factors
4 Recruiting Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Recurrent Intraocular Melanoma
Interventions: Biological: recombinant interferon alfa-2b;   Drug: dacarbazine;   Other: laboratory biomarker analysis
5 Recruiting Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Conditions: Mucosal Melanoma;   Acral Melanoma;   Melanoma
Intervention: Drug: Nilotinib
6 Recruiting Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
Conditions: Recurrent Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: Aurora A kinase inhibitor MLN8237;   Other: laboratory biomarker analysis;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Procedure: biopsy;   Genetic: protein expression analysis;   Other: immunohistochemistry staining method;   Genetic: TdT-mediated dUTP nick end labeling assay;   Other: cell proliferation assay;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: mass spectrometry;   Other: liquid chromatography;   Genetic: microarray analysis;   Procedure: fluorescence spectroscopy
7 Not yet recruiting Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Drug: Axitinib
8 Not yet recruiting Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Conditions: Melanoma;   Metastatic Melanoma
Interventions: Drug: Vemurafenib;   Drug: Bevacizumab
9 Recruiting Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Conditions: Melanoma;   NY-ESO-1-positive;   Progressive Metastatic Cutaneous Melanoma;   Unresectable
Intervention: Biological: GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)
10 Recruiting SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Conditions: Mucosal Melanoma;   Acral/Lentiginous Melanoma
Intervention: Drug: SU011248
11 Recruiting Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Melanoma
Conditions: Metastatic Melanoma;   Cutaneous Melanoma
Interventions: Drug: Interferon alpha;   Drug: KW2871;   Drug: interferon alpha
12 Recruiting Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Conditions: Malignant Melanoma Stage III;   Malignant Melanoma Stage IV
Intervention: Biological: TriMix-DC and ipilimumab
13 Recruiting Panobinostat (LBH589) in Patients With Metastatic Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Drug: LBH589
14 Recruiting Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Drug: CT-011
15 Recruiting Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma
Conditions: Melanoma;   Metastatic Melanoma;   Solid Tumor
Intervention: Drug: MLN2480
16 Recruiting Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Conditions: Stage IIIC Melanoma;   Stage IV Melanoma
Intervention: Drug: Denileukin diftitox
17 Recruiting Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Biological: ipilimumab;   Drug: cyclophosphamide;   Procedure: biopsy;   Biological: aldesleukin;   Other: immunohistochemistry staining method;   Genetic: polymerase chain reaction;   Other: immunoenzyme technique;   Biological: therapeutic allogeneic cytotoxic T lymphocytes
18 Recruiting Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Biological: CD40 agonist monoclonal antibody CP-870,893;   Biological: tremelimumab;   Other: laboratory biomarker analysis
19 Recruiting Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Drug: cyclophosphamide;   Biological: aldesleukin;   Biological: autologous tumor cell vaccine;   Other: laboratory biomarker analysis;   Other: immunologic technique;   Other: immunohistochemistry staining method;   Genetic: polymerase chain reaction;   Biological: therapeutic autologous lymphocytes
20 Recruiting Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Drug: temozolomide;   Other: flow cytometry;   Other: staining method;   Procedure: biopsy;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40)
† Indicates status has not been verified in more than two years
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services